Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829155 | 0.85 | PPARA (0.51) | PPARACTSSPPARGNPSR1KLK7 | |
| SCHEMBL6482683 | 0.85 | PPARA (0.51) | PPARACTSSPPARGNPSR1KLK7 | |
| SCHEMBL4669396 | 0.81 | KLK7 (0.41) | PPARACTSSPPARGNPSR1L3MBTL1 | |
| SCHEMBL26986079 | 0.80 | PPARA (0.50) | PPARACTSSPPARGNPSR1L3MBTL1 | |
| SCHEMBL4545478 | 0.79 | PPARA (0.48) | PPARACTSSPPARGNPSR1L3MBTL1 | |
| SCHEMBL19215337 | 0.78 | PPARA (0.46) | PPARACTSSPPARGL3MBTL1SYK | |
| SCHEMBL26985988 | 0.77 | PPARA (0.52) | PPARACTSSPPARGNPSR1L3MBTL1 | |
| SCHEMBL26985920 | 0.77 | CA1 (0.55) | PPARACTSSPPARGNPSR1L3MBTL1 | |
| SCHEMBL9427199 | 0.77 | L3MBTL1 (0.49) | PPARACTSSPPARGNPSR1L3MBTL1 | |
| SCHEMBL18601225 | 0.77 | PPARA (0.46) | PPARACTSSPPARGNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288213-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL|ACETIC ACID DERIVATIVES | KANEKA CORP (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060246557-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7094594-B2 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20050080277-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1288213-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246557-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | HAAO, APEH, HPD | PPARA 1157/4885CTSS 4262/4885PPARG 1757/4885 |
| US-20050080277-A1 | Process for preparing optically active 2-[6-(hydroxy-methyl)-1,3-dioxan-4-yl] acetic acid derivatives | HAAO, APEH, HPD | PPARA 1081/4885CTSS 4118/4885PPARG 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.